• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
184205 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  . t0 L, D) i* F, ?

- C5 h  @- R- Z* Z7 V* n* F# N5 ]; |1 h, w8 H
Sub-category:4 I- ?/ u; Z4 j* k% M6 V
Molecular Targets
& S# M* r0 f, Q4 S. T/ K
; Q9 d. P6 h% {! g! U; C
2 q/ ^7 \& f( X$ @Category:: T* @( S3 W8 _' F# z4 L
Tumor Biology 1 x  x0 w# B: R( A1 i/ T
( H/ c  y5 l, _( v2 A

* K/ F9 `6 c$ h# u5 ?( TMeeting:
: K; u* F& E6 Z* @2011 ASCO Annual Meeting 8 C) i/ J; j- v) b7 p) y9 b

2 h$ y- Z5 {- I: w' x: ~2 S0 H3 S2 J  R  Z! e2 |3 f
Session Type and Session Title:
: s2 X1 Z2 V, T) V% P4 G, S* cPoster Discussion Session, Tumor Biology 5 c4 _3 }2 f' x4 e) a2 `

: e3 d* a  k% t: Z/ Q9 a
# T- L9 m) J9 o+ z4 p2 e! CAbstract No:( Q" R% C+ \8 \! H1 C" a4 b# o: Y
10517 $ {/ |5 z. [# q/ d8 J
# _9 y( T; @# l4 X7 G8 |

8 D) v: f. S- L+ n  CCitation:* W8 I) S7 i; B8 k' {% f5 e+ k) k
J Clin Oncol 29: 2011 (suppl; abstr 10517) ) p, \# j; {. ]5 f# W

8 g. H2 e, x) u: J* K$ q5 y
; e9 Y) `; N. J7 TAuthor(s):
$ v# n. d6 _4 {& S0 {" a9 }+ S! I8 |J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* s9 W0 ?6 k" f+ c7 n4 b
. P, Z+ B/ P! V* ?# D3 H  w/ F  U. U4 e; @) a+ M3 o) G6 M: ]8 Z
& a$ D" x. ^! V
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
  N7 X, A5 F  O$ _$ w% l3 v" h
5 v5 u) I5 Q) S8 M  ]+ v( c6 SAbstract Disclosures
5 J2 p' r# B7 n: k8 \
9 J9 q- D  l  ?, |+ c% d; ?0 jAbstract:
( H% T, P: K6 P( Y" B" ?1 l* R+ K' @, Q+ l/ \

8 F: @: E6 ], [; _; FBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
' |# C1 j2 ]* L1 w* n, X2 ?; h) z% `. C! ]5 K( R4 ]% u* a
2 l$ t" c, N% d# s1 r' `$ D
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
7 k/ t5 p3 i3 k" Q; Q没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

) U2 {) l2 U; x/ t1 ]$ O: W9 a化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 % H8 d4 Q6 l7 v' o, O4 T( [
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。! _- @8 c+ r+ ^* W3 q0 P9 w
ALK一个指标医院要900多 ...
/ Z+ L# r9 {, R5 k, k
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 V3 S/ K, |% |/ O6 `! B: u- t6 R% n6 D4 F- ^+ L6 v! v
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表